- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference, Noel Clarke presents the role of PARP inhibitors for all patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Noel Clarke, MBBS, FRCS, ChM, Professor of Urological Oncology, Salford Royal Hospital & The Christie NHS Foundation Trust, Manchester, UK Related Content: APCCC 2022: Debate: PARP Inhibitors for All...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Heather Cheng presents the importance of lifestyle and prevention of complications in advanced prostate cancer, focusing on how we should take care of our patient’s muscle strength. Biographies: Heather H. Cheng, MD, PhD, Director, Seattle Cancer Care Alliance Prostate Cancer Genetics Clinic, Division of Medical Onco...
|
- Details
- During the session of the 2022 Advanced Prostate Cancer Consensus Conference focusing on the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), Anwar Padhani presents risk-adapted treatment monitoring in mCRPC (which imaging methods, when and how often). Biographies: Anwar Padhani, MBBS, FRCP, FRCR, Consultant, Radiologist & Professor, Cancer Imaging, Paul Strickla...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Neal Shore presents the role of radium-223 in the modern treatment armamentarium in metastatic castration-resistant prostate cancer (mCRPC) patients. Biographies: Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, Sout...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Gert Attard presents on whether we need more granularity in mHSPC, and whether biology can help with treatment decisions. Biographies: Gert Attard, MD, PhD, FRCP, John Black Charitable Foundation Endowed Chair in Urological Cancer Research, University College London Cancer Institute, London, UK Related Content: APCCC...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022), Ian Davis presents when low-volume disease on conventional imaging becomes high-volume on next-generation imaging in mHSPC, we should treat these patients like high-volume patients. This is a part of a point-counter-point discussion "When Low-Volume on Conventional Imaging Goes Into High-Volume on Next-Generation Imaging in mH...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Oliver Sartor presents on the importance of lifestyle and prevention of complications in advanced prostate cancer focusing on how we should take care of our patient’s bones. Biographies: A. Oliver Sartor, MD, Professor of Medicine, Urology, and Radiology, Director Radiopharmaceutical Trials, Mayo Clinic, Rochester, M...
|
- Details
- Kim Chi presents an overview of how to read a genomics testing report during APCCC 2022. His presentation includes a discussion of prostate cancer-relevant genes, reading the FoundationOne CDx test, and more. Chi explains the importance of understanding the intricacies of the genomics report and its limitations given that tumor genomics is now a standard part of the workup for patients with advanc...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Matthew Smith presents the role of prostate-specific membrane antigen (PSMA)-lutetium radionuclide therapy, including considerations regarding monotherapy, combination therapy, and patient selection. Biographies: Matthew R. Smith, MD, Ph.D., Professor of Medicine, Harvard Medical School, Assistant in Medicine, Hematology/Oncology,...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Maha Hussain presents the optimal treatment sequencing in metastatic castration-resistant prostate cancer (mCRPC). Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Division of Hematology-Oncology, Department of Medicine, and the Deputy Director at the Robert H. Lurie Comprehensive Can...
|
